About this trial
CALD is an inflammatory demyelinating disease that causes severe motor and cognitive deficit leading to rapid death. Hematopoietic stem cell transplantation (HSCT) can halt neuroinflammation in CALD through the replacement of microglia (i.e., brain immune system) but only if performed during its early phase.
Using standard brain MRI, it is estimated that only 30% of adult CALD patients are identified. Complex and lengthy clinical evaluations together with MRI reading from experts improve CALD detection but are not available in routine clinical practice.
Diffusion tensor imaging is a quantitative microstructural technique that can identify neuroinflammation at a very early stage. Still, its implementation in clinical practice has been very limited due to high inter-center measurements variability and bias due to data quality issues. The approach we will use solves these problems by introducing an automatic calibration and standardization with systematic quality control enabling the use of all MRI scanners in clinical settings.
The innovative aspect of this project lies on the validation of an expert-independent prognosis biomarker able to specifically identify patients at high-risk to convert to CALD so that treatment can be initiated at the early stage of neuroinflammation.
We aim to demonstrate that this tool has at least a 2-fold sensitivity compared to the current standard of care.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
> 18 years old
Male gender
Genetically diagnosed with ALD by carrying an ABCD1 pathogenic variant
Signed written informed consent
Disqualifiers
Patient with non-arrested CALD
Other neurological conditions such as brain tumour, stroke or a traumatic head injury
Contraindication to MRI (claustrophobia, implanted metal components in the head, panic disorder, epilepsy)
People under legal protection measure (tutorship, curatorship or safeguard measures)
Trial population
Adult males carrying an ABCD1 pathogenic variant
Trial design
Cohort
Prospective
Treatments tested in this trial
brainQuant module of brainTale-care platform
DevicebrainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
Treatment groups
Trial outcomes
Primary outcomes
Sensitivity of RD-index19 change of at least 1 point between two consecutive annual measurements to diagnose CALD before or at the same time than the reference diagnostic made by an expert committee
The expert committee comprising 3 experts in neuroradiology blinded to the RD-index19 change results. The study aims to demonstrate that RD-index19-change of at least 1 point between two consecutive annual measurements has a sensitivity significantly greater than 60% to detect CALD conversion before or at the same time as the best experts in the field of CALD diagnosis.
Specificity of RD-index19 change of at least 1 point between two consecutive annual measurements with repect to CALD conversion before or at the same time than the reference diagnostic made by an expert committee
The expert committee comprising 3 experts in neuroradiology blinded to the RD-index19 change results. The study aims to demonstrate that RD-index19-change of at least 1 point between two consecutive annual measurements has a specificity significantly greater than 80% with repect to CALD conversion before or at the same time as the best experts in the field of CALD diagnosis.
Secondary outcomes
Sensitivity values of plasma NfL with regard to CALD diagnosis
Specificity values of plasma NfL with regard to CALD diagnosis
Sensitivity values of FA-index19-change with regard to CALD diagnosis
Specificity values of FA-index19-change with regard to CALD diagnosis
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Braintale
Collaborator
This trial is not recruiting at the moment. You can still explore other options: